Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment

被引：0
|
作者：
Rafael Morales-Barrera
Guillermo Villacampa
Natalia Vidal
Mariona Figols
Julia Giner
Teresa Bonfill
Cristina Suárez
Nely Díaz
Joaquín Mateo
Macarena González
Montserrat Domenech
Javier Puente
Joan Carles
机构：
[1] Vall d’Hebron Institute of Oncology,Department of Medical Oncology
[2] Vall d’ Hebron University Hospital,Oncology Data Science (OdysSey) Group
[3] Universitat Autònoma de Barcelona,Medical Oncology Department
[4] Vall d’Hebron Institute of Oncology (VHIO),Medical Oncology Department
[5] The Institute of Cancer Research,Medical Oncology
[6] Hospital Clínico San Carlos,undefined
[7] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC),undefined
[8] CIBERONC,undefined
[9] Fundació Althaia Manresa,undefined
[10] Parc Taulí Hospital Universitari,undefined
[11] Institut d’Investigació i Innovació Parc Taulí I3PT,undefined
来源：
Clinical and Translational Oncology | 2023年 / 25卷
关键词：
Immune checkpoint inhibitors; Immune-related adverse events; Overall response rate; Survival; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3556 / 3564
页数：8
相关论文
共 50 条
  • [1] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Morales-Barrera, Rafael
    Villacampa, Guillermo
    Vidal, Natalia
    Figols, Mariona
    Giner, Julia
    Bonfill, Teresa
    Suarez, Cristina
    Diaz, Nely
    Mateo, Joaquin
    Gonzalez, Macarena
    Domenech, Montserrat
    Puente, Javier
    Carles, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (12): : 3556 - 3564
  • [2] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
    Das, Satya
    Johnson, Douglas B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [3] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yoshikawa, Yuki
    Imamura, Michio
    Yamauchi, Masami
    Hayes, C. Nelson
    Aikata, Hiroshi
    Okamoto, Wataru
    Miyata, Yoshihiro
    Okada, Morihito
    Hattori, Noboru
    Sugiyama, Kazuhiko
    Yoshioka, Yukio
    Toratani, Shigeaki
    Takechi, Masaaki
    Ichinohe, Tatsuo
    Ueda, Tsutomu
    Takeno, Sachio
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Teishima, Jun
    Hide, Michihiro
    Nagata, Yasushi
    Kudo, Yoshiki
    Iida, Koji
    Chayama, Kazuaki
    BMC CANCER, 2022, 22 (01)
  • [4] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yuki Yoshikawa
    Michio Imamura
    Masami Yamauchi
    C. Nelson Hayes
    Hiroshi Aikata
    Wataru Okamoto
    Yoshihiro Miyata
    Morihito Okada
    Noboru Hattori
    Kazuhiko Sugiyama
    Yukio Yoshioka
    Shigeaki Toratani
    Masaaki Takechi
    Tatsuo Ichinohe
    Tsutomu Ueda
    Sachio Takeno
    Tsuyoshi Kobayashi
    Hideki Ohdan
    Jun Teishima
    Michihiro Hide
    Yasushi Nagata
    Yoshiki Kudo
    Koji Iida
    Kazuaki Chayama
    BMC Cancer, 22
  • [5] Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
    Leucht, Katharina
    Ali, Nalyan
    Foller, Susan
    Grimm, Marc-Oliver
    CANCERS, 2022, 14 (18)
  • [6] Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
    Muir, Christopher A.
    Clifton-Bligh, Roderick J.
    Long, Georgina, V
    Scolyer, Richard A.
    Lo, Serigne N.
    Carlino, Matteo S.
    Tsang, Venessa H. M.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3704 - E3713
  • [7] Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
    Kobayashi, Kazuo
    Suzuki, Kenichi
    Hiraide, Makoto
    Aoyama, Takeshi
    Yokokawa, Takashi
    Shikibu, Sari
    Hashimoto, Koki
    Iikura, Yusuke
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    ONCOLOGY, 2020, 98 (04) : 237 - 242
  • [8] Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.
    Morales-Barrera, Rafael
    Suarez Rodriguez, Cristina
    Gonzalez, Macarena
    Ros, Javier
    Eugenia Semidey, Maria
    Hernandez, Ester Serra
    Mateo, Joaquin
    Saez, Carlos Fernandez
    Lozano, Fernando
    Mast, Richard
    Roche, Sarai
    Quintana, Angela
    Gutierrez Fernandez, Sara
    Serrano, Cesar
    Valverde, Claudia
    de Torres, Ines
    Maldonado, Xavier
    Morote, Juan
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events
    Nizam, Amanda
    Rader, Ryan K.
    Tzeng, Alice
    Wei, Wei
    Sheng, Iris Yeong-Fung
    Martin, Allison
    Wee, Christopher E.
    Gilligan, Timothy D.
    Gupta, Shilpa
    Ornstein, Moshe C.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 368 - 379
  • [10] Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).
    Vitale, Nuzzo Pier
    Pond, Gregory Russell
    Abou Alaiwi, Sarah
    Nassar, Amin
    Flippot, Ronan
    Choueiri, Toni K.
    Harshman, Lauren Christine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345